CARsgen Therapeutics Holdings Limited

Equities

2171

KYG1996C1006

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 01:38:17 17/05/2024 pm IST			5-day change	1st Jan Change
6.55 ^HKD	+7.38%		+9.35%	+0.77%

30/04	CARsgen Therapeutics Holdings Limited Announces Abstracts from the Ongoing Studies of zevorcabtagene autoleucel and CT071 to be Presented as an Oral Presentation and a Poster Presentation, Respectively, at the Upcoming EHA 2024	CI
29/04	CARsgen Therapeutics Holdings Limited Announces Board and Committee Changes	CI

CARsgen Therapeutics Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2023

August 22, 2023 at 04:30 pm IST

CARsgen Therapeutics Holdings Limited reported earnings results for the half year ended June 30, 2023. For the half year, the company reported net loss was CNY 404.47 million compared to CNY 376.34 million a year ago. Basic loss per share from continuing operations was CNY 0.73 compared to CNY 0.69 a year ago.

Latest news about CARsgen Therapeutics Holdings Limited

CARsgen Therapeutics Holdings Limited Announces Abstracts from the Ongoing Studies of zevorcabtagene autoleucel and CT071 to be Presented as an Oral Presentation and a Poster Presentation, Respectively, at the Upcoming EHA 2024	30/04	CI
CARsgen Therapeutics Holdings Limited Announces Board and Committee Changes	29/04	CI
CARsgen Therapeutics Holdings Limited Submits Responses to FDA Observations	29/04	CI
Carsgen Therapeutics To Give Cancer Drug Oral Presentation at ASCO 2024	12/04	MT
CARsgen Therapeutics Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	26/03	CI
CARsgen Therapeutics’ New Drug Application for Multiple Myeloma Drug Gets Approval from Chinese Regulator	01/03	MT
National Medical Products Administration of China Approves New Drug Application of CARsgen Therapeutics Holdings Limited for Zevorcabtagene Autoleucel	01/03	CI
CARsgen Presents Data from Phase 1B Study on Gastric, Gastroesophageal Junction Cancer Drug at US Meet	19/01	MT
Carsgen Therapeutics Holdings Limited Announces Updated Clinical Research Results on CT041 at 2024 ASCO GI Meeting	19/01	CI
China Grants CARsgen Clinical Trial Clearance for Liver Cancer Treatment; Shares Rise 3%	15/01	MT
CARsgen Therapeutics Holdings Limited Announces CT011 Achieve Investigational New Drug Clearance from the National Medical Products Administration	15/01	CI
CARsgen Therapeutics Holdings Shareholder Plans Stake Boost; Shares Fall 6%	18/12	MT
US FDA Puts CARsgen's Three Drug Candidates Under Clinical Hold Following Factory Inspections; Shares Plummet 27%	13/12	MT
CARsgen Therapeutics Presents Anti-Cancer Drug Data at American Conference	12/12	MT
CARsgen Therapeutics Holdings Presents Results of Study for Myeloma Treatment	12/12	MT
CARsgen Therapeutics Holdings Limited Announces Updated Research Results on Zevor-cel At 2023 American Society of Hematology Annual Meeting	12/12	CI
CARsgen Therapeutics Holdings Limited Receives Investigational New Drug Clearance from the FDA for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma	04/12	CI
US FDA Grants Investigational New Drug Clearance for CARsgen Therapeutics' Anti-Tumor Drug	04/12	MT
CARsgen to Present Abstract for Gastric, Pancreatic Cancer Drug in US Oncology Meet	15/11	MT
CARsgen to Present Immunotherapy Research at US Hematology Conference	20/23/20	MT
CARsgen Therapeutics Holdings Limited Announces Abstract of Zevorcabtagene Autoleucel Accepted for Poster at 2023 Ash Annual Meeting	20/23/20	CI
Catalyst Pharmaceuticals Names Richard Daly as Chief Executive	19/23/19	MT
CARsgen Therapeutics Holdings Limited Car-Gpc3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Two Patients Achieved over 7 Years of Disease-Free Survival	12/23/12	CI
CARsgen and Moderna to Collaborate for Cancer Medication	22/23/22	MT
CARsgen Therapeutics Holdings Limited Announces Collaboration Agreement for Zevor-Cel Commercialization in Mainland China with Huadong Medicine	22/23/22	CI

Chart CARsgen Therapeutics Holdings Limited

Duration

Period

Chart CARsgen Therapeutics Holdings Limited

More charts

Company Profile

CARsgen Therapeutics Holdings Ltd is a China-based investment holding company principally engaged in discovering, developing and commercializing innovative chimeric antigen receptor (CAR)-T cell therapies. The Companyâs therapies are applied in the treatment of hematological malignancies and solid tumors. The Company have developed an upgraded B cell maturation antigen (BCMA) targeted CAR-T product, CT053, which is its sole core product candidate. The Company conducts its businesses in China and the United States.

Sector

Biotechnology & Medical Research

Calendar

20/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

6.063 CNY

Average target price

6.662 CNY

Spread / Average Target

+9.87%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CARSGEN THERAPEUTICS HOLDINGS LIMITED	+0.77%	45Cr
VERTEX PHARMACEUTICALS INCORPORATED	+9.02%	11TCr
REGENERON PHARMACEUTICALS, INC.	+11.42%	10TCr
BIONTECH SE	-12.38%	2.24TCr
ARGENX SE	-1.05%	2.23TCr
GENMAB A/S	-5.29%	1.91TCr
WUXI APPTEC CO., LTD.	-38.29%	1.8TCr
BEIGENE, LTD.	-2.72%	1.79TCr
NEUROCRINE BIOSCIENCES, INC.	+8.07%	1.43TCr
SAREPTA THERAPEUTICS, INC.	+35.06%	1.25TCr

Bio Therapeutic Drugs